Patents by Inventor Benjamin Kleinstiver

Benjamin Kleinstiver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS
    Publication number: 20260240960
    Abstract: Methods and compositions for reducing expansion of nucleotide repeats in a cell, comprising base editors and a guide RNA (gRNA) that directs the Cas-based enzyme to the splice acceptor site for mutL homolog 3 (MLH3) exon 7 or to the MLH3 endonuclease domain.
    Type: Application
    Filed: August 24, 2023
    Publication date: August 20, 2026
    Inventors: Ricardo Mouro Pinto, Benjamin Kleinstiver
  • Variants of CRISPR from and 1 (Cpf1)
    Patent number: 12649913
    Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: June 9, 2026
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Variants of CRISPR from and 1 (Cpf1)
    Patent number: 12590299
    Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 31, 2026
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
    Publication number: 20250382597
    Abstract: Streptococcus pyogenes Cas9 (SpCas9) variants with relaxed PAM requirements capable of high-resolution editing for various applications, and methods of use thereof.
    Type: Application
    Filed: May 23, 2025
    Publication date: December 18, 2025
    Inventors: Benjamin Kleinstiver, Russell T. Walton
  • CRISPR-Cas Enzymes with Enhanced On-Target Activity
    Publication number: 20250382595
    Abstract: Engineered versions of Streptococcus pyogenes Cas9 (SpCas9) and SpCas9 variants that have improved on-target editing capabilities, and methods of use thereof.
    Type: Application
    Filed: February 26, 2025
    Publication date: December 18, 2025
    Inventors: Benjamin Kleinstiver, Russell T. Walton
  • Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
    Patent number: 12312613
    Abstract: Streptococcus pyogenes Cas9 (SpCas9) variants with relaxed PAM requirements capable of high-resolution editing for various applications, and methods of use thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: May 27, 2025
    Assignee: The General Hospital Corporation
    Inventors: Benjamin Kleinstiver, Russell T. Walton
  • Methods for increasing efficiency of nuclease-induced homology-directed repair
    Patent number: 12286641
    Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: April 29, 2025
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Jason Michael Gehrke, Shengdar Tsai, James Angstman, Rebecca Tayler Cottman
  • CRISPR-ASSOCIATED TRANSPOSASES AND METHODS OF USE THEREOF
    Publication number: 20250122535
    Abstract: Described herein are improved CRISPR-associated transposases (CASTs), including homing endonuclease-assisted large-sequence integrating CRISPR-associated transposases (CAST) complexes and methods of use thereof, and other strategies to improve the activities of natural and engineered CASTs.
    Type: Application
    Filed: December 2, 2022
    Publication date: April 17, 2025
    Inventors: Benjamin Kleinstiver, Connor J. Tou
  • CRISPR-Cas enzymes with enhanced on-target activity
    Patent number: 12264341
    Abstract: Engineered versions of Streptococcus pyogenes Cas9 (SpCas9) and SpCas9 variants that have improved on-target editing capabilities, and methods of use thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: April 1, 2025
    Assignee: The General Hospital Corporation
    Inventors: Benjamin Kleinstiver, Russell T. Walton
  • Engineered CRISPR-Cas9 nucleases with altered PAM specificity
    Patent number: 12241096
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: February 24, 2023
    Date of Patent: March 4, 2025
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
    Patent number: 12202861
    Abstract: Drug-inducible, tunable, and multiplexable Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1)-based activators, and methods of use thereof.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: January 21, 2025
    Assignee: The General Hospital Corporation
    Inventors: Y. Esther Tak, Benjamin Kleinstiver, J. Keith Joung
  • Engineered CRISPR-Cas9 nucleases with altered PAM specificity
    Patent number: 12180520
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: December 31, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Variants of Cpf1 (Cas12a) with altered PAM specificity
    Patent number: 12173339
    Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with improved targeting range and enhanced on-target activity, and their use in genomic engineering, epigenomic engineering, base editing, genome targeting, genome editing, and in vitro diagnostics.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: December 24, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Alexander Sousa
  • Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity
    Publication number: 20240150741
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Genome editing approaches to treat Spinal Muscular Atrophy
    Publication number: 20240066102
    Abstract: Described herein are methods and compositions for treating subjects with spinal muscular atrophy (SMA) using CRISPR editing of exon 7 and/or intron 7 of SMN2.
    Type: Application
    Filed: January 10, 2022
    Publication date: February 29, 2024
    Inventors: Benjamin Kleinstiver, Christiano Robles Alves, Kathryn J. Swoboda, Kathleen A. Christie
  • Engineered CRISPR-Cas9 nucleases with altered PAM specificity
    Patent number: 11859220
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 2, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Inducible, Tunable, and Multiplex Human Gene Regulation Using CRISPR-Cpf1
    Publication number: 20230416310
    Abstract: Drug-inducible, tunable, and multiplexable Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1)-based activators, and methods of use thereof.
    Type: Application
    Filed: April 20, 2023
    Publication date: December 28, 2023
    Inventors: Y. Esther Tak, Benjamin Kleinstiver, J. Keith Joung
  • Engineered CRISPR-Cas9 Nucleases with Altered PAM Specificity
    Publication number: 20230407277
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Application
    Filed: February 24, 2023
    Publication date: December 21, 2023
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
    Patent number: 11667677
    Abstract: Drug-inducible, tunable, and multiplexable Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1)-based activators, and methods of use thereof.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: June 6, 2023
    Assignee: The General Hospital Corporation
    Inventors: Y. Esther Tak, Benjamin Kleinstiver, J. Keith Joung
  • Engineered CRISPR-Cas9 nucleases with altered PAM specificity
    Patent number: 11624058
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: February 17, 2022
    Date of Patent: April 11, 2023
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver